Cellectis SA
(STU:ZVA)
€
1.442
0 (0%)
Market Cap: 150.14 Mil
Enterprise Value: -12.25 Mil
PE Ratio: 0
PB Ratio: 1.29
GF Score: 66/100 - Q3 2024 Cellectis SA Earnings Call TranscriptNov 05, 2024€1.68 (-0.24%)Earnings
- Q1 2024 Cellectis SA Earnings Call TranscriptMay 29, 2024€2.36 (-2.48%)Earnings
- Q3 2023 Cellectis SA Earnings Call TranscriptNov 07, 2023€2.51 (-5.28%)Earnings
- Cellectis SA at Jefferies Cell & Genetic Medicine Summit TranscriptSep 26, 2023
- Q2 2023 Cellectis SA Earnings Call TranscriptAug 04, 2023€1.77 (+0.80%)Earnings
- Cellectis SA at Goldman Sachs Healthcare Conference TranscriptJun 15, 2023
- Q1 2023 Cellectis SA Earnings Call TranscriptMay 05, 2023€1.81 (+14.71%)Earnings
- Cellectis SA at Barclays Global Healthcare Conference TranscriptMar 14, 2023
- Q4 2022 Cellectis SA Earnings Call TranscriptMar 09, 2023€2.02 (-0.10%)Earnings
- Cellectis SA Corporate Analyst Meeting (Virtual) TranscriptDec 13, 2022
- Q3 2022 Cellectis SA Earnings Call TranscriptNov 04, 2022€2.17 (-13.74%)Earnings
- Atara Biotherapeutics Inc, Cellectis SA and 2Seventy Bio Inc at Citi BioPharma Conference- Panel TranscriptSep 07, 2022
- Q2 2022 Cellectis SA Earnings Call TranscriptAug 05, 2022€3.25 (+8.99%)Earnings
- Cellectis SA at Goldman Sachs Global Healthcare Conference TranscriptJun 16, 2022
- Cellectis SA at JMP Securities Life Sciences Conference TranscriptJun 16, 2022
- Q1 2022 Cellectis SA Earnings Call TranscriptMay 13, 2022€2.91 (+1.54%)Earnings
- Cellectis SA at Barclays Global Healthcare Conference TranscriptMar 17, 2022
- Q4 2021 Cellectis SA Earnings Call TranscriptMar 04, 2022€3.4 (-2.69%)Earnings
- Cellectis SA at Barclays Gene Editing & Gene Therapy Summit (Virtual) TranscriptNov 15, 2021
- Q3 2021 Cellectis SA Earnings Call TranscriptNov 05, 2021€10.6 (+1.34%)Earnings
- Cellectis SA at Citi BioPharma Conference (Virtual) TranscriptSep 09, 2021
- Q2 2021 Cellectis SA Earnings Call TranscriptAug 06, 2021€11.98 (+5.46%)Earnings
- Cellectis SA at Barclays Global Healthcare Conference (Virtual) TranscriptMar 10, 2021
- Q4 2020 Cellectis SA Earnings Call TranscriptMar 05, 2021€15.92 (-5.80%)Earnings
- Cellectis SA at Barclays Virtual Gene Editing & Gene Therapy Summit - Presentation TranscriptNov 16, 2020
- Q3 2020 Cellectis SA Earnings Call TranscriptNov 06, 2020€14.34 (-2.05%)Earnings
- Cellectis SA at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) TranscriptSep 17, 2020
- Q2 2020 Cellectis SA Earnings Call TranscriptAug 06, 2020€15 (+3.31%)Earnings
- Cellectis SA Chardan Leadership Call TranscriptMay 27, 2020
- Q1 2020 Cellectis SA Earnings Call TranscriptMay 07, 2020€12.8 (+2.56%)Earnings
- Q4 2019 Cellectis SA Earnings Call TranscriptMar 05, 2020€13.5 (-6.57%)Earnings
- Q3 2019 Cellectis SA Earnings Call TranscriptNov 07, 2019€11.58 (+5.27%)Earnings
- Cellectis SA at Citi Biotech Conference TranscriptSep 04, 2019
- Cellectis SA at Goldman Sachs Global Healthcare Conference TranscriptJun 13, 2019
- Cellectis SA at Barclays Global Healthcare Conference TranscriptMar 13, 2019
- Q4 2018 Cellectis SA Earnings Call TranscriptMar 12, 2019€15.71 (+0.26%)Earnings
Cellectis SA at Goldman Sachs Healthcare Conference Transcript
Jun 15, 2023 / 05:00PM GMT
Release Date Price:
€1.87
(-0.95%)
Anoumid Vaziri
Goldman Sachs Group, Inc., Research Division - Research Analyst
Good morning, everyone. I'm Anoumid Vaziri. And I'm joined on stage with Bing Wang, CFO of Cellectis. Bing, thank you for being here with us today.
Bing C. Wang
Cellectis S.A. - CFO
Thank you for inviting me.
Questions & Answers
Anoumid Vaziri
Goldman Sachs Group, Inc., Research Division - Research Analyst
And so to start, Cellectis is a clinical stage biotech company using its TALENs gene editing platform to develop allogeneic cell therapies. Could you provide an overview of your portfolio, both on the partnered and the wholly-owned assets and then discuss how you're differentiated as a company in the cell therapy space?
Bing C. Wang
Cellectis S.A. - CFO
Great. Thank you very much. So I would say we would put our portfolio in 3 buckets. The first is our wholly-owned clinical asset. So we have UCART22 going after ALL. We have UCART123 going after AML. We can go into that in
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)